The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Items 101–200 of 541
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
“Currently, it is unclear whether psychological or neurobiological effects mediate the therapeutic properties of psychedelics (for an overview of the current debate with examples, see 10, 11).”
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 49
“As other researchers have commented (Kazdin, 2007; Yaden & Griffiths, 2020), such specificity is important to establish in order to attribute therapeutic changes directly to particular acute experiences (and not, e.g., to the general intensity of the drug effect), a difficult task given high levels…”
InfluentialBenefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 37
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 41
Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Lee, A., Rosenbaum, D., & Buchman, D. Z. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231225937 · Cited by 35
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D. J., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 42
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
“While the role of psychedelic-induced subjective effects in therapeutic outcomes is still highly debated 20,21 , the importance of structural plasticity has been appreciated as a hallmark of antidepressant efficacy for many years 1,4,22,23 .”
New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
Noorani, T. N., & Martell, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727050 · Cited by 38
Pearson, C. S., Siegel, J. S., & Gold, J. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120096 · Cited by 36
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Self-citationSoares, C., Mier, G. G., Castelhano, J., & Castelo-Branco, M. S. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105325 · Cited by 32
Emmerich, N., & Humphries, B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000099 · Cited by 37
Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation
Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000270 · Cited by 31
“3,4,5 Although nonsubjective psychedelics currently do not exist, interest in developing such compounds from private companies and other stakeholders is currently growing.”
Self-citationA Transformative Trip? Experiences of Psychedelic Use
Neitzke‐Spruill, L., Beit, C. S., Robinson, J. O., Blevins, K. R., Reynolds, J., Evans, N. G., & McGuire, A. L. (2024) · Neuroethics · doi:10.1007/s12152-024-09567-0 · Cited by 31
“First, the relevance of subjective experience to the benefits of psychedelics has been debated in recent years owing to findings in the basic neurosciences, which suggest that psychedelics can facilitate several forms of neuroplasticity [42–45].”
BackgroundOptimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 32
History repeating: A roadmap to address common problems in psychedelic sciencePreprint
van Elk, M., & Fried, E. I. (2023) · doi:10.31234/osf.io/ak6gx · Cited by 30
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
“Supporting this hypothesis, the reduction in prefrontal 5-HT2AR activity resulting from classical hallucinogens could explain certain aspects of their impact on depression and anxiety [211].”
BackgroundBhatt, K. V., & Weissman, C. R. (2024) · npj Mental Health Research · doi:10.1038/s44184-023-00053-8 · Cited by 34
“While research continues to investigate physiological mechanisms through which psilocybin induces therapeutic effects, many experts propose that the subjective psychedelic experience, often termed the mystical experience, is a necessary component 15 .”
BackgroundThe Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item
Strickland, J. C., Garcia‐Romeu, A., & Johnson, M. W. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0046 · Cited by 30
“40,41 Brief measures may allow for additional opportunities to test these hypotheses by allowing for more inclusive measurement in clinical protocols and in potential future nonresearch clinical care settings.”
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 32
“Although some consider mystical experiences to be crucial to the therapeutic use of psyche-delics (Yaden & Griffiths, 2021), there is some contention around this point (e.g., Olson, 2020).”
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study
Wood, M. J., McAlpine, R. G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-79931-w · Cited by 33
Dose-response relationships of LSD-induced subjective experiences in humans
Hirschfeld, T., Prugger, J., Majić, T., & Schmidt, T. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01588-2 · Cited by 32
“There is some evidence that the quality and 75 intensity of acute psychedelic effects might predict therapeutic outcome [18].”
BackgroundThal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 38
Ayahuasca for the Treatment of Depression
Palhano-Fontes, F., Soares, B. L., Coelho, N. L. G., Arcoverde, E., & de Araújo, D. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_277 · Cited by 35
Effects of classic psychedelic drugs on turbulent signatures in brain dynamics
Cruzat, J., Perl, Y. S., Escrichs, A., Vohryzek, J., Timmermann, C., Roseman, L., Luppi, A. I., Ibáñez, A. M., Nutt, D., Carhart-Harris, R. L., et al. (2022) · Network Neuroscience · doi:10.1162/netn_a_00250 · Cited by 31
“…speculate that increased long-range information transfer under psychedelics relates to their purported ability to facilitate psychological insight (Yaden & Griffiths, 2020)—consistent with the etymology of the term “psychedelic”—that is, “mind-revealing” (Hartogsohn, 2018; Nichols, 2016; Osmond,…”
BackgroundCan psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 33
“, 2018) embedded in subjective changes in affect, time, space, embodiment and empathy (Preller and Vollenweider, 2018), as well as what some would call ‘mystical experiences’ and the insights drawn from their contents (Yaden and Griffiths, 2021).”
BackgroundKaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 33
“The alternative proposal is that subjective experiences hold the key to the success of psychedelic interventions (32, 33).”
BackgroundKelly, T. J., Bonniwell, E. M., Mu, L., Liu, X., Hu, Y., Friedman, V., Yu, H., Su, W., McCorvy, J. D., & Liu, Q.-S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01744-8 · Cited by 35
Psychedelics as Therapeutics—Potential and Challenges
Volkow, N. D., Gordon, J. A., & Wargo, E. M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1968 · Cited by 29
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“There is an ongoing debate over whether the hallucinogenic effects of serotonergic psychedelics are dissociable from the therapeutic effects (Olson, 2020; Yaden and Griffiths, 2020).”
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
“As with ketamine, whether the intensity of these subjective effects is positively correlated with antidepressant effects is still debated (Olson, 2021; Yaden and Griffiths, 2021).”
Psychedelic Medicine Exceptionalism
Cohen, I. G., & Marks, M. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2025.2434398 · Cited by 29
“Study participants sometimes describe them as ranking among the most meaningful experiences of their lives (Yaden and Griffiths 2021).”
Addressing blinding in classic psychedelic studies with innovative active placebos
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D’Souza, D. C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf023 · Cited by 33
“…psilocybin produced significantly greater scores on insight and mystical-type experiences than high-dose DXM—a finding that might be especially important if the therapeutic effects of classic psychedelics are driven in part by the acute subjective experience, as suggested by some 33 but not others.”
Nautiyal, K. M., & Yaden, D. B. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01424-z · Cited by 28
“However, the use of active placebos in clinical trials and the key experiment (referred to by Yaden and Griffiths as a “critical test” [2]) in which psychedelics are given to patients under anesthesia are important approaches to examine the potential causal role of the subjective conscious experience in the clinical e…”
Self-citationNikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 28
Self-citationThe mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
“A counterargument is encapsulated by the behavioral catalyst model, which postulates that the psychedelic experience and psychological insights gained are central to producing long-term changes in behavior and relief of symptoms [72].”
BackgroundPsychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 28
“In light of the increasingly recognized clinical success of their approach, they saw the burden of proof on the side of those who claimed that psychedelic effects were dispensable (Yaden and Griffiths 2021).”
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 30
“…are not just an unnecessary side-effect but constitutive for therapeutic effects: even when the rated intensity of the overall drug effects is statistically controlled for, the more mystical patients rate their psychedelic experience, the greater the therapeutic effects (Yaden & Griffiths, 2020).”
Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy
Harrison, T. R., Faber, S. C., Zare, M., Fontaine, M., & Williams, M. T. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433423 · Cited by 28
“Both classical and empathogenic psychedelics have been shown to produce senses of meaning, feelings of euphoria, and perceptual changes while inducing altered states of consciousness (Hovmand, Poulsen, and Arnfred 2024; Yaden and Griffiths 2021).”
Psychopharmacology and Explanatory Pluralism
Aftab, A., & Stein, D. J. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0470 · Cited by 32
Eckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13410 · Cited by 25
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 26
“Nevertheless, there is an ongoing debate regarding the necessity of the subjective effects of psychedelics for their enduring therapeutic efficacy (Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundAverill, L. A., & Abdallah, C. G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2035358 · Cited by 23
“as Yaden and Griffith note, ‘it seems unlikely that rodents would have experiences similar to those to which humans attribute deep personal meaning and positive, therapeutically relevant mood and behavioral change after taking a psychedelic [44],’”
BackgroundPsychedelic Psychotherapy: Building Wholeness Through Connection
Vaid, G., & Walker, B. (2022) · Global Advances in Health and Medicine · doi:10.1177/2164957x221081113 · Cited by 26
“Receptor level activity, enhanced neuroplasticity and connectivity support a trans-diagnostic mechanism of action and treatment approach 8, 9, 10, 11 while corresponding changes in subjective experience, emotional processing, intersubjectivity and social cognition appear to contribute to the therapeutic efficacy.(12,1…”
BackgroundGattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
“The involvement of the 5-HT 2A receptor and the hallucinogenic experience in psilocybin efficacy is of continual debate (Cameron et al., 2021; Yaden & Griffiths, 2020).”
Toward a Broader Psychedelic Bioethics
Jacobs, E., Yaden, D. B., & Earp, B. D. (2023) · AJOB Neuroscience · doi:10.1080/21507740.2023.2188281 · Cited by 24
Self-citationHumphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 32
Psychedelic Mystical Experience: A New Agenda for Theology
Cole‐Turner, R. (2022) · Religions · doi:10.3390/rel13050385 · Cited by 25
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 28
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 28
2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C. W., & Merryman, W. D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01178 · Cited by 24
Bedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 28
Wolfson, P., & Vaid, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1209419 · Cited by 34
The future of psychiatry: clinical practice, diagnosis, and treatment
Turner, S., Yadav, P., Morrin, H., & Bhat, A. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2594523 · Cited by 23
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
“Participants in clinical trials often describe their experiences as emotionally intense and personally meaningful—and many attribute subsequent improvements in mood, behavior or worldview to these moments of insight or catharsis 199 .”
The altered state of consciousness induced by Δ9-THC
Murray, C. H., & Desikan, B. S. (2022) · Consciousness and Cognition · doi:10.1016/j.concog.2022.103357 · Cited by 23
“The subjective effects of these compounds may be instrumental in mediating therapeutic outcomes (Preller et al., 2017; Yaden & Griffiths, 2021), and more broadly, may aid in empirical studies of consciousness (Bayne & Carter, 2018; Yaden & Griffiths, 2021).”
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
Jensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 26
Jensen, M. E., Stenbæk, D. S., Messell, C., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319457 · Cited by 25
“Five of the seven responders, but none of the three non-responders, met Pahnke’s criteria for a ‘complete’ mystical experience (Pahnke, 1969), defined as scoring more than 60% of the maximum on each of MEQ30’s four subscales (Yaden and Griffiths, 2020).”
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 24
Moreton, S. G., Burden-Hill, A., & Menzies, R. E. (2022) · Clinical Psychologist · doi:10.1080/13284207.2022.2086793 · Cited by 19
Moreton, S. G., Arena, A. F. A., Foy, Y., & Menzies, R. E. (2023) · Death Studies · doi:10.1080/07481187.2023.2169848 · Cited by 23
A novel ego dissolution scale: A construct validation study
Sleight, F. G., Lynn, S. J., Mattson, R. E., & McDonald, C. W. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103474 · Cited by 22
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 24
“In contrast, psychological and phenomenological research is targeted toward the subjective features of psychedelic experiences that predict therapeutic success (Roseman et al., 2018; Yaden and Griffiths, 2021).”
BackgroundPsychedelics and neonihilism: connectedness in a meaningless world
Plesa, P., & Petranker, R. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1125780 · Cited by 23
“Psychedelics users report increased subjective feelings of meaning following their experience, which has been suggested as a required mediator for improved mental health (Yaden and Griffiths, 2021).”
BackgroundPsychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 31
“The patients required observation up to 24 h after treatment [127].”
Bonnelle, V., Feilding, A., Rosas, F. E., Nutt, D. J., Carhart-Harris, R. L., & Timmermann, C. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241276788 · Cited by 24
Classification schemes of altered states of consciousness
Fort, L. D., Costines, C., Wittmann, M., Demertzi, A., & Schmidt, T. T. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106178 · Cited by 34
“Yet, these experiences appear relevant in modern psychiatry, particularly in studies involving psy-chedelic compounds (Griffiths et al., 2008; MacLean et al., 2011; Rotz et al., 2023; Timmermann et al., 2024; Yaden and Griffiths, 2021).”
Psychedelic Epistemology: William James and the “Noetic Quality” of Mystical Experience
Cole‐Turner, R. (2021) · Religions · doi:10.3390/rel12121058 · Cited by 24
Reduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics
Stoliker, D., Egan, G. F., & Razi, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.827400 · Cited by 24
Modlin, N. L., Creed, M., Sarang, M., Maggio, C., Rucker, J., & Williamson, V. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s432537 · Cited by 24
“…after PT. Reported changes in self-narratives may be catalysed or accompanied by the previously highlighted mechanisms of change in PT. 56,71,118,119 Further, increases in caring emotional responses towards self, 57 connectedness towards others, 55 experience of positive affect 120 and health…”
BackgroundBasedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 23
Calder, A. E., Rausch, B., Liechti, M. E., Holze, F., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278873 · Cited by 20
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 24
The energy resistance principle
Picard, M. A., & Murugan, N. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.09.002 · Cited by 22
Newton, K., & Moreton, S. G. (2022) · Ecopsychology · doi:10.1089/eco.2022.0044 · Cited by 22
“Emerging research suggests that it may be the acute psychological experiences that psychedelics induce, rather than solely their physiological effects, that may be crucial in understanding the enduring positive outcomes (Olson, 2020; Yaden & Griffiths, 2020).”
How Do Psychedelics Reduce Fear of Death?
Letheby, C. (2024) · Neuroethics · doi:10.1007/s12152-024-09564-3 · Cited by 20
“However, as others have emphasized, the many strong correlations between aspects of the acute psychedelic experience and lasting psychological benefits are most readily explained if the latter are caused primarily by the former [44].”
Validation of the imperial psychedelic predictor scale
Angyus, M., Osborn, S., Haijen, E., Erritzoe, D., Peill, J., Lyons, T., Kettner, H., & Carhart-Harris, R. (2024) · Psychological Medicine · doi:10.1017/s0033291724002204 · Cited by 11
“…experience have been found to be predictive of subsequent positive and negative therapeutic outcomes (Herrmann et al., 2022; Roseman, Nutt, & Carhart-Harris, 2018), indicating the nature of experience may be an important determinant of subsequent therapeutic trajectories (Yaden & Griffiths, 2020).”
BackgroundArtru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 22
Rodríguez‐Cano, B. J., Kohek, M., Oña, G., Alcázar‐Córcoles, M. Á., SANTOS, R. G. D., Hallak, J. E. C., & Bouso, J. C. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13587 · Cited by 20
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
Cherniak, A. D., Brulin, J. G., Mikulincer, M., Östlind, S., Carhart-Harris, R. L., & Granqvist, P. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148061 · Cited by 31
“…and phenomenological states clearly are associated with brain processes (Carhart-Harris et al., in press), we tentatively follow the mounting evidence for a phenomenological position; RSMEs appear to facilitate the clinical utility of psychedelic-assisted therapy (Yaden & Griffiths, 2021).”
Tap, S. C. (2024) · Addiction Biology · doi:10.1111/adb.13386 · Cited by 17
“35,105 Second, the study found significant acute increases in theta (6 – 8 Hz) in most subjects during 5-MeO-DMT.”
BackgroundInfluentialPsychedelics and disorders of consciousness: the current landscape and the path forward
Cardone, P., Alnagger, N., Annen, J., Bicego, A., Gosseries, O., & Martial, C. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae025 · Cited by 19
“…such substance would have huge implications on the nature of the relationship between complexity and consciousness, as well as understanding if clinical changes could be attributed to the subjective experience (Yaden and Griffiths 2020) or to its underlying neurophysiological effects (Olson 2021).”
BackgroundWalther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
“These insights are frequently cited as fundamentally important to enduring positive outcomes in therapy, mediating improvements in, for example, well-being, psychological flexibility, depression, anxiety, and substance use [84].”
InfluentialRediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 32
“In summary, the importance of the psychedelic experience for the therapeutic effects of psilocybin remains controversial [69,72] and will be a subject for further studies.”
BackgroundArmstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 24
“” Both mindfulness meditation (336, 337) and psychedelic experiences (246, 338, 339) appear to facilitate insight, which may result in part from the “ decentering ” effects (e.g., disruption of the DMN) and which likely contributes to therapeutic effects of both modalities.”
BackgroundMallaroni, P., Mason, N. L., Vinckenbosch, F. R. J., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06142-4 · Cited by 18
“2018; Yaden and Griffiths 2020).”
Backgroundvan Oorsouw, K. I. M., Uthaug, M. V., Mason, N. L., Broers, N. J., & Ramaekers, J. G. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00174 · Cited by 19
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach
Agin-Liebes, G., & Davis, A. K. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_282 · Cited by 22
Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025) · Journal of Fungi · doi:10.3390/jof11020099 · Cited by 15
“Most studies consistently show that the intensity of experience, its positive valence or the ability to achieve mystical experiences are predictors of a long-lasting response [63,64].”
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 17
Psychedelics align brain activity with context
Stoliker, D., Novelli, L., Khajehnejad, M. A., Biabani, M., Greaves, M. D., Barta, T., Williams, M., Chopra, S., Bazin, O., Simonsson, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10910-z · Cited by 26
Madrid-Gambín, F., Gomez‐Gómez, À., Busquets-García, A., Haro, N., Marco, S., Mason, N. L., Reckweg, J. T., Mallaroni, P., Kloft, L., van Oorsouw, K. I. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112845 · Cited by 18
“Interestingly, it has been suggested that cluster A effects are related to enduring therapeutic outcomes [81].”
BackgroundPsilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
“Theoretically, an active placebo that mimics psychedelic effects without providing therapeutic benefit might appear appropriate for this purpose, although one would argue that it may well be the “mystical state” itself that may drive the beneficial effects [31,32,82].”
Backgroundvan den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
“effects are essential for the antidepressant effects as demonstrated, for example, by three RCTs with psilocybin that show correlations between the intensity of the acute mystical experience and the long-lasting therapeutic effects in depression, anxiety, and nicotine addiction (Yaden and Griffiths 2021).”
BackgroundDavid, J., Bouso, J. C., Kohek, M., Oña, G., Tadmor, N., Arnon, T., Dor‐Ziderman, Y., & Berkovich‐Ohana, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1287961 · Cited by 14
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 17
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.